

Serial No.: 09/250,083

-4-

Group Art Unit: 1631

Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims**1-21. (Canceled)**

**22. (Currently Amended)** A method of identifying an inhibitors of cPLA<sub>2</sub> activity comprising:

(a) providing a potential inhibitor compound; and

(b) ~~determining whether the potential inhibitor inhibits the activity of cPLA<sub>2</sub>, wherein said inhibitor~~ identifying whether the compound interacts with one or more atoms of ~~said~~ one or more amino acids in the cPLA<sub>2</sub> active site, and wherein said one or more atoms is selected from the group consisting of:

CB and Oy atoms of Ser228;

Oδ1 and Oδ2 atoms of Asp549 and Asp575;

CB, CG, CD, NE, CZ, NH1 and NH2 atoms of Arg200, Arg413 and Arg579;

Backbone carbonyl oxygen of Trp393;

Nδ2 and Oδ1 atoms of Asn555;

Atoms CD1, CE1, CG, CZ, CE2, and CD2 of Phe397, Phe681, Phe683 and Phe199;

CG, CD1, NE1, CE2, CZ2, CH2, CZ3, CE3 and CD2 of Trp232 and Trp393;

CB and Oy atoms of Ser577;

Atom s CB and Sy of Cys331;

Atoms OE1 and OE2 of Glu589;

Atoms CB, CG, CD, CE and NZ of Lys588;

Oy1 atom of Thr680;

OE1 and OE2 atoms of Glu418 and Glu422;

Serial No.: 09/250,083

-5-

Group Art Unit: 1631

Atoms CB, CG, SD and CE of Met417;  
Atoms CB, CG, CD1 and CD2 of Leu400 and Leu421;  
Atoms CB, CG1, CG2, or CD1 of Ile424;  
Backbone NH and carbonyl oxygen atoms of Ala578; and  
Atoms CB, CG, ND1, CE1, NE2, and CD2 of His639; and  
(c) assaying the ability of the compound to inhibit cPLA<sub>2</sub> activity,  
thereby identifying an inhibitor of cPLA<sub>2</sub> activity.

23-29. (Canceled)

30. (Currently Amended) The method of claim 22, wherein said activity of cPLA<sub>2</sub> is ~~lipid binding phospholipid metabolism~~.

31. (Previously presented) The method of claim 22, wherein said activity of cPLA<sub>2</sub> is membrane binding.

32. (New) The method of claim 22, wherein said activity of cPLA<sub>2</sub> is cleavage of the *sn*-2 ester of a glycerophospholipidic substrate.

33. (New) The method of claim 22, wherein said compound has an IC<sub>50</sub> value of less than about 25  $\mu$ M in the soluble substrate assay.

34. (New) The method of claim 22, wherein said compound has an IC<sub>50</sub> value of less than about 5 $\mu$ M in the vesicle assay.

35. (New) The method of claim 22, wherein said compound has an IC<sub>50</sub> value of less than about 1 $\mu$ M in the PMN assay.